Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Der Kommentar von Lorenz wurde ignoriert. Um die Kommentare von Lorenz wieder zu sehen, klicken Sie folgenden Link:
Hier kommt heute scon wieder Erfreuliches:
Aurora Cannabis to Acquire Cannabis Science Leader Anandia Laboratories Inc.
Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and Anandia Laboratories Inc. (“Anandia“) announced today that they have signed a binding term sheet whereby Aurora intends to acquire all of the issued and outstanding common shares of privately-held Anandia in an all share transaction valued at approximately $115 million on a fully diluted basis (the “Transaction”).
Led by CEO and co-founder Jonathan Page , PhD, one of the industry’s most widely recognized cannabis experts, Anandia is considered the industry leader in science, genetics, and independent cannabis product testing. Dr. Page was the first scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids and the interplay between cannabinoids and terpenes.
Anandia’s COO and co-founder, John Coleman , PhD, brings over 20 years of experience in drug research and commercialization as a natural product chemist. He previously worked in the biotech industry, most recently leading the team identifying new drug targets for the federally funded Centre for Drug Research and Development.
Anandia’s intellectual property (“IP”) includes the exclusive rights to a number of key genes in the cannabinoid pathway, as well as patents pending for genetic markers. The strength of Anandia’s expert staff, proprietary assets and know-how will provide Aurora with a very significant advantage in developing new cannabis cultivars. For instance, genome-based variety development and technological fortification can tailor metabolite (cannabinoid and terpene) profiles, improve disease resistance, enhance crop yield and optimize flowering time, and can be employed to develop specialized cultivars for oil production.
In advance of the forthcoming legalization of the adult use market and the significant associated growth, Anandia intends to expand its R&D, product testing, and product development facilities to meet both domestic and international demand, including the development of:
Anandia follows a three-pronged approach to creating value for its clients licensed under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) and intends to continue to do so following completion of the Transaction:
Combining with Aurora gives Anandia access to significant new market opportunities in Canada and internationally through Aurora’s global footprint. Furthermore, leveraging Aurora’s capabilities and capacity in facility development, the combination will accelerate the construction of Anandia’s testing and product development laboratory in Vancouver , and a unique, purpose-built cannabis breeding facility ahead of Canadian adult-use legalization,
Anandia’s Product Testing
Anandia’s cannabis testing services will remain operationally independent of Aurora. These services will remain intact and Anandia is committed to continuing to serve all clients, including Licensed Producers and patient-growers, and Anandia is committed to maintaining complete data confidentiality. Anandia will continue to build capacity to take on the increased sample volume arising from legalization, including expansion to its new testing facility in Vancouver .
“This is a transformative acquisition that expands our science capabilities in the upstream segment of the seed-to-sale cannabis value chain, significantly boosting plant-based innovations in cultivation, enabling accelerated product development, and, ultimately, enhancing our margin profile going forward,” said Terry Booth , CEO of Aurora. “Anandia has a fantastic, complementary corporate culture and some of the best and brightest minds in the cannabis industry, including Dr. Jonathan Page , the first scientist to sequence the cannabis genome. By adding Dr. Page and the Anandia team to the existing Aurora and CanniMed research infrastructure, we are assembling a unique, world-class research group to capitalize on the many exciting opportunities the cannabis plant offers society.”
Dr. Jonathan Page , Anandia’s co-founder and CEO, added, “Anandia is already on its way to developing a world-leading library of cannabis genetics coupled with in-depth genomic analysis. We expect our breeding efforts to be accelerated through access to Aurora’s financial resources and scientific expertise, as well as through the addition of Aurora’s multiple cultivation sites. Anandia and Aurora are strong believers in research and science-based solutions. Joining forces with Aurora allows us to continue to provide best-in-class testing services to our customers, while rapidly advancing cannabis science for the benefit of patients, consumers and growers.”
Und von gestern noch dies:
Hier noch was von CGC (ich habe momentan grad keine, warte mal, wie das so kommt an der US-Börse)
Canopy to go ahead with pot trials to treat insomnia
2018-06-12 09:58 ET - News Release
Mr. Mark Zekulin reports
MEDICAL CANNABIS LEADERSHIP FROM CANOPY GROWTH AND SUBSIDIARY SPECTRUM CANNABIS
Canopy Growth Corp. has provided the following updates on its medical cannabis program and has reaffirmed its strong commitment to medical cannabis, the patients who depend on it and the health care professionals who prescribe it.
Historic clinical trial milestones
Marking a major milestone for medical cannabis in Canada, a phase IIb in-human clinical trial application was submitted by Canopy Health Innovations Inc. to evaluate the use of medical cannabis in the treatment of insomnia. Having received approval to proceed with these clinical trials in the form of a no objection letter (NOL) from Health Canada, Canopy Health will now proceed with these robust clinical trials, in collaboration with a leading Canadian research institution.
In light of the significant potential for cannabis in treating a range of medical conditions, this is the first in a planned series of trials to investigate and quantify the therapeutic effect of cannabis and cannabinoids across a selection of indications with significant unmet needs, working toward the ultimate goal of patented, insurance-eligible cannabinoid-based medicines.
World-class leadership for a global industry
As previously announced, starting in July, 2018, Dr. Mark Ware will commence his role as the company's chief medical officer. Under his leadership the company will continue to lead the global medical cannabis industry forward with a focus on research, product innovation and stakeholder education in the numerous regions where Spectrum Cannabis operates, including Latin America, Australia, Europe and North America.
Patients-first pricing mentality
Honouring the company's commitment to affordable medical cannabis and pricing predictability for patients, Canopy Growth is pleased to inform patients that, upon the passing of the Cannabis Act, the company will absorb the proposed excise tax on all Spectrum Cannabis products sold in Canada. Affordability is a key consideration for patients. It is important today to show leadership and reduce the price burden placed on customers, while the company works toward insurance eligibility for medical cannabis.
On top of this, all Spectrum Cannabis dried flower products will be priced at $8.50 per gram or less. If a registered customer is currently paying more for a Spectrum flower product this means new savings, and if they are paying less that price will remain the same. As always, Spectrum Cannabis products available on-line through the Tweed Main Street website are eligible for the company's industry-first compassionate pricing program that assists those on limited incomes afford their medicine.
"Using Canada's rich ecosystem of researchers and established cannabis stakeholders as a centre of expertise, Spectrum's global expansion is rooted in sophistication," said Mark Zekulin, president, Canopy Growth. "We are proudly a research- and patient-focused company that will continue to drive the cannabis innovation agenda forward around the world."
Here is to future growth.
About Canopy Growth Corp.
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
Und von gestern die News.
Der Kommentar von Selector wurde ignoriert. Um die Kommentare von Selector wieder zu sehen, klicken Sie folgenden Link:
Ja, hier geht was zurzeit:
Aurora Cannabis to acquire 8% of Choom Holdings
2018-06-13 08:02 ET - News Release
Mr. Terry Booth reports
AURORA CANNABIS TO BE LEAD INVESTOR IN CHOOM HOLDINGS PRIVATE PLACEMENT
Aurora Cannabis Inc. intends to complete a $7-million investment in Choom Holdings Inc., whereby Aurora will receive 9,859,155 common shares from Choom's treasury, priced at 71 cents per share, representing an 8-per-cent ownership interest.
Choom currently operates two late-stage applicants under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Choom has agreements in place to acquire two additional late-stage applicant craft growers in British Columbia and Saskatchewan, including a facility in Sooke, B.C., anticipated to receive its cultivation licence from Health Canada in the third quarter of 2018.
The relationship between Aurora and Choom germinated through Aurora Pro, the platform through which the company delivers a variety of services to industry participants, including cultivation, genetics, regulatory consultancy and market development services. The Aurora Pro platform was developed by Aurora to interact with craft growers who are faced with potentially unreasonable entry barriers to the adult usage market in Canada.
Choom's strategy is to develop a carefully curated portfolio of high-grade cannabis strains with ideal characteristics for craft growing, targeting the premium segment of the adult consumer use market. Choom continues to develop a sophisticated brand, high-grade products and an elevated in-store customer experience. Images of the company's concept cannabis retail outlets can be found on-line.
To date, Choom has secured rights to 17 retail leases in highly defensible locations throughout Alberta. Applications to obtain a cannabis retail licence for these outlets have been submitted. Choom also has seven leases secured in B.C. and licences will be applied for upon commencement of the licensing program in B.C. Choom furthermore intends to play an important role in the Saskatchewan retail market and has a robust strategy in place to develop its presence in this market.
"Our investment in a consumer-focused brand with a strong retail strategy offers Aurora additional growth opportunities through supply, retail and distribution to the adult consumer use market, and provides a good example of the functioning of Aurora Pro," said Terry Booth, chief executive officer of Aurora. "Choom has established a well-developed brand, supported by deep roots within the British Columbia cannabis community and a passion for high-grade, handcrafted product. We're excited to strengthen our relationship with the team at Choom and help amplify their market reach as they continue to execute on their differentiated craft growing philosophy and their unique retail strategy."
Chris Bogart, president and CEO for Choom, added: "Teaming up with what we consider to be the most dynamic licensed producer with exceptional strength throughout the entire cannabis value chain, we believe, will prove to be a key growth accelerator for Choom. Both companies have a very strong focus on the entire customer experience, key in establishing exceptional brands. This investment by Aurora is a strong signal to our markets and our shareholders that Choom's strategy meets with the highest standards in the industry."
About Aurora Cannabis Inc.
Aurora's wholly owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, known as Aurora Mountain, and a second 40,000-square-foot high-technology production facility known as Aurora Vie in Pointe-Claire, Que., on Montreal's West Island. In January, 2018, Aurora's 800,000-square-foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed by Health Canada. Once at full capacity, Aurora Sky is expected to produce over 100,000 kilograms per annum of cannabis.
About Choom Holdings Inc.
Choom was created for and inspired by the Choom gang, a group of buddies in Honolulu during the 1970s who loved to smoke weed -- or as the locals called it, choom. Now, after four decades, Choom is bringing the spirit of Hawaii to Canada. Choom is focused on delivering an elevated customer experience through its curated retail environments, high-grade handcrafted cannabis supply and a diversity of brands for the Canadian recreational consumer.
Dann war da noch:
Der Kommentar von Emil wurde ignoriert. Um die Kommentare von Emil wieder zu sehen, klicken Sie folgenden Link:
27. Juni 2018
Danke, ich werde hinschauen und ev. vielleicht, möglicherweise noch vorher...
Hier noch was von
ACB, da ist jemand ganz schön überzeugt, es geht auch in die richtige Richtung mit dem Kurs:
Dienstag, 19.06.2018 - 20:16 Uhr
Cannabis-Aktien gehen durch die Decke!
Heute machen die Cannabis-Aktien erneut einen kräftigen Sprung nach oben. Der Grund hierfür ist in Canada zu finden. Die Legalisierung von Cannabis ist durch! >
Das kam heute noch durch die News (s. Link):
Aurora Cannabis to spin out U.S. assets into separate company
Canada's second largest cannabis company plans to place its U.S. assets into a new separate company that will focus on investing in the cannabis and real estate sector there.
Canadian shareholders will receive 1 share in new company for every 20 Aurora shares they own...
Nur noch zur Info, bin da nicht mehr drin, aber die Zahlen interessieren vermutlich.
Canopy Growth slips 5% post Q4 results
Jun. 27, 2018 10:10 AM ET|About: Canopy Growth Corporation (CGC)|By: Vandana Singh, SA News Editor
Canopy Growth (CGC -5.2%) reports Q4 sales of C$22.8M, up 55% Y/Y attributable to launch of Spectrum Softgels, strong sales Canada, Germany, as well as expansion in Africa, Europe and Australia.
Sold 2,528 (+45%) kilograms and kilogram equivalent cannabinoids, at an average sales price of C$8.43 per gram (5%).
Adjusted EBITDA amounted to a loss of C$22.9M compared to loss of C$0.1M last year.
Cannabinoids harvested increased 143% to 4,811 kilograms.
Inventory stood at 15,726 kilograms of dry cannabis, 6,969 litres of cannabis oil and 356 kilograms of softgel capsules.
The company ended with C$323M in cash & cash equivalents.
Previously: Canopy Growth misses by $0.23, misses on revenue (June 27)
Click to subscribe to real-time analytics on CGC
Danke für die Info oben.
Aurora (News von gestern):
Aurora Cannabis Announces $200 Million Debt Facility with BMO
Major Non-Dilutive Financing Deal with Canadian Tier 1 Bank Represents Significant Milestone in the Cannabis Sector
EDMONTON, June 26, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that it has agreed to a new $200 million debt facility, with a potential upsize to $250 million, with the Bank of Montreal ("BMO").
The facility will consist of a $150 million term loan and a $50 million revolving credit facility (together, the "Loans"), both of which will mature in 2021. A short period after the implementation of Bill C-45 in October 2018, the Company may request an increase of up to a further $45 million to the term loan subject to agreement by BMO and satisfaction of certain legal and business conditions. BMO will also be providing up to $5 million in other credit instruments. Closing of the debt facility is subject to completion of final due diligence, negotiation of definitive documentation, and satisfaction of conditions precedent customary to a financing of this nature.
The debt facility will be primarily secured by Aurora's production facilities, including Aurora Sky, Aurora Mountain, and Aurora Vie. Strategically located at Edmonton International Airport, Aurora Sky is the world's most technologically advanced cannabis facility, projected to produce in excess of 100,000 kg per year of high-quality cannabis at low per gram costs, and slated to deliver its first harvest this week.
"Having successfully met all of BMO's stringent risk assessment and other due diligence criteria to establish this facility reflects well on the maturity, progress and prospects of Aurora, as well as the quality and economic value of our production facilities," said Terry Booth, CEO. "This is by far the largest traditional debt facility in the cannabis industry to date. The funds provide us additional fuel to complement our end-to-end portfolio of vertically integrated, geographically and horizontally diversified assets, aimed at building a pre-eminent global cannabis company with a superior margin profile."
Glen Ibbott, CFO of Aurora, added, "The shift to traditional debt financing is significant. Our cost of capital continues to decrease, providing us a distinct competitive advantage as we execute on our growth strategy. The non-dilutive nature and attractive pricing are consistent with Aurora's commitment to generating shareholder value. We believe this is a major milestone in the cannabis industry and a validation of our operational effectiveness. It also marks an exciting new stage of our long-term relationship with BMO, a Tier 1 bank with a sterling domestic and international reputation."
The Loans can be repaid without penalty at Aurora's discretion. The pricing of the Loans is a set margin over the BMO CAD Prime Rate or a Bankers' Acceptance of appropriate term. Based on the current BMO CAD Prime Rate, the interest payable is expected to be in the mid to high 4% per annum range over the term of the Loans.
More details on this new sector benchmark debt facility can be found in the Company's documents once filed on www.sedar.com.
Und Anfang diese Woch noch ein Video:
Aurora ist echt superkommunikativ, dies ist alles von heute. Da weiss man wenigstens was abgeht. Ich muss das via Link reingeben, ist zuviel Text sonst.
Der Kommentar von petra129 wurde ignoriert. Um die Kommentare von petra129 wieder zu sehen, klicken Sie folgenden Link:
Valuation Model On Public Traded Companies July 2018
Compared to their peers – Undervalued Marijuana Stocks by Rank.
7-11 - overvalued.
Read more at http://www.stockhouse.com/companies/bullboard#1rK8IitDKb965X6c.99
Canopy Growth Corporation to Announce First Quarter Fiscal 2019 Financial Results
August 1, 2018
SMITHS FALLS, ON—Canopy Growth Corporation (TSX:WEED, NYSE:CGC) (“Canopy Growth”) will release its financial results for the first quarter fiscal 2019 ended June 30, 2018 on August 14, 2018.
Der Kommentar von Chrigu wurde ignoriert. Um die Kommentare von Chrigu wieder zu sehen, klicken Sie folgenden Link:
Hat der Hipe bereits nachgelassen oder vorübergehendes Tief aufgrund Handelskrieg? Ich bin in WEEDTQ LEON C 04/21 investiert.
Nicht zu gierig werden vs. Hin und Her macht Taschen leer
© 1998-2018 / cash
| Impressum |